Neurocrine Biosciences
NBIX
#1366
Rank
$15.50 B
Marketcap
$155.51
Share price
0.84%
Change (1 day)
21.74%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): $4.31

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $4.31. In 2024 the company made an earnings per share (EPS) of $3.38 an increase over its 2023 EPS that were of $2.54.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)$4.3127.51%
2024$3.3833.07%
2023$2.5457.76%
2022$1.6169.47%
2021$0.95-78.21%
2020$4.36990%
2019$0.4081.82%
2018$0.22-113.5%
2017-$1.630.62%
2016-$1.6257.28%
2015-$1.0325.61%
2014-$0.8218.84%
2013-$0.69-1085.71%
2012$0.07000

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
$0.03000-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
$1.77-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
-$61.00-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
$20.52 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
$1.35-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$1.72-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
$1.71-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-$2.03-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA